AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 28 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Octavalent pneumococcal vaccines conjugated to either diphtheria toxoid or tetanus protein stimulated different serotype responses but offered similar protection to immunized children.
Sigurveig T. Sigurdardottir and collaborators at Landspitali-University Hospital in Iceland conducted a trial involving 160 infants who received one of two octavalent pneumococcal vaccines at the ages of 3, 4, and 6 months.
The vaccines, containing serotypes 3, 4, 6B, 9V, 14, 18C, 19F and 23F, were conjugated either to diphtheria toxoid (PncD) or tetanus protein (PncT). When the children reached the age of 13 months, they received a booster of the same conjugate or of a 23-valent polysaccharide vaccine. The investigators measured antibody levels at 3, 4, 6, 7, 13 and 14 months by ELISA.
Children in both groups developed significant levels of IgG antibodies to all serotypes by 7 months. The PncT conjugate vaccine elicited IgG geometric mean concentrations from 0.35 to 4.09 micrograms/mL, resulting in 88.2 to 100% of the children reaching antibody levels of at least 0.15 micrograms/mL; the antibody range produced by the PncD conjugate was 0.65 to 3.38 micrograms/mL, with 92.4 to 100% of children achieving antibody levels of at least 0.15 micrograms/mL.
A greater response to the 3, 9V, and 18C serotypes was provoked by the PncD vaccine, while the PncT elicited a stronger serotype 4 response. Both booster inoculations elicited a strong antibody reaction, with 97.5 to ...
Source: HighBeam Research, Researchers design a better pneumococcal vaccine.(Brief Article)